Key Takeaways from the FDA's First Draft Guidance on Clinical Trials with Psychedelic Drugs | Foley & Lardner LLP

On June 26, 2023, the U.S. Food and Drug Administration (FDA) issued its first draft guidance entitled Psychedelic Drugs: Considerations for Clinical Investigations Guidance for...

Related Keywords

,Drug Enforcement Administration ,Drug Administration ,Marketing Authorization For Pharmaceuticals ,Foley Lardner ,Psychedelic Drugs ,Clinical Investigations Guidance ,International Council ,Technical Requirements ,Human Use ,Nonclinical Safety Studies ,Human Clinical Trials ,Marketing Authorization ,Controlled Substances Act ,Controlled Substances Staff ,Drug Evaluation ,